Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerald Reischl

Showing results (71-80 of 105) with videos related to

Pageof 11
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 11, 2017
In Vivo Hypoxia PET Imaging Quantifies the Severity of Arthritic Joint Inflammation in Line with Overexpression of Hypoxia-Inducible Factor and Enhanced Reactive Oxygen Species GenerationKerstin Fuchs, Anna Kuehn, Moritz Mahling, et al.
Frontiers in Nuclear Medicine|October 2, 2024
Cyclotrons Operated for Nuclear Medicine and Radiopharmacy in the German Speaking D-A-CH Countries: An Update on Current Status and TrendsClaus Zippel, Johannes Ermert, Marianne Patt, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 30, 2025
One-day dual-tracer examination in neuroendocrine neoplasms: a real advantage of low activity LAFOV PET imagingEduardo Calderón, Lena S Kiefer, Fabian P Schmidt, et al.
Brain : a Journal of Neurology|September 13, 2015
No parkinsonism in SCA2 and SCA3 despite severe neurodegeneration of the dopaminergic substantia nigraLudger Schöls, Matthias Reimold, Kay Seidel, et al.
Clinical Nuclear Medicine|January 25, 2024
Radiosensitizing Favors Response to Peptide Receptor Radionuclide Therapy in Patients With Highly Proliferative Neuroendocrine Malignancies: Preliminary Evidence From a Clinical Pilot StudyNils Florian Trautwein, Clemens Hinterleitner, Lena Sophie Kiefer, et al.
Science Advances|October 25, 2024
Functional PET/MRI reveals active inhibition of neuronal activity during optogenetic activation of the nigrostriatal pathwaySabrina Haas, Fernando Bravo, Tudor M Ionescu, et al.
Oncotarget|April 13, 2016
Preclinical evaluation of the anti-tumor effects of the natural isoflavone genistein in two xenograft mouse models monitored by [18F]FDG, [18F]FLT, and [64Cu]NODAGA-cetuximab small animal PETValerie S Honndorf, Stefan Wiehr, Anna-Maria Rolle, et al.
Theranostics|June 28, 2019
Imaging fibrosis in inflammatory diseases: targeting the exposed extracellular matrixNicolas Beziere, Kerstin Fuchs, Andreas Maurer, et al.
Neuroimage|November 24, 2007
[11C]PIB binding in Parkinson's disease dementiaWalter Maetzler, Matthias Reimold, Inga Liepelt, et al.
EJNMMI Physics|February 5, 2025
Low-activity [<sup>18</sup>F]-somatostatin receptor (SSTR) imaging using [<sup>18</sup>F]SiTATE on a long axial field-of-view PET/CT scannerNils F Trautwein, Eduardo Calderón, Pia M Linder, et al.
Pageof 11

Showing results (71-80 of 105) with videos related to

Sort By:
Pageof 11
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 11, 2017
In Vivo Hypoxia PET Imaging Quantifies the Severity of Arthritic Joint Inflammation in Line with Overexpression of Hypoxia-Inducible Factor and Enhanced Reactive Oxygen Species GenerationKerstin Fuchs, Anna Kuehn, Moritz Mahling, et al.
Frontiers in Nuclear Medicine|October 2, 2024
Cyclotrons Operated for Nuclear Medicine and Radiopharmacy in the German Speaking D-A-CH Countries: An Update on Current Status and TrendsClaus Zippel, Johannes Ermert, Marianne Patt, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 30, 2025
One-day dual-tracer examination in neuroendocrine neoplasms: a real advantage of low activity LAFOV PET imagingEduardo Calderón, Lena S Kiefer, Fabian P Schmidt, et al.
Brain : a Journal of Neurology|September 13, 2015
No parkinsonism in SCA2 and SCA3 despite severe neurodegeneration of the dopaminergic substantia nigraLudger Schöls, Matthias Reimold, Kay Seidel, et al.
Clinical Nuclear Medicine|January 25, 2024
Radiosensitizing Favors Response to Peptide Receptor Radionuclide Therapy in Patients With Highly Proliferative Neuroendocrine Malignancies: Preliminary Evidence From a Clinical Pilot StudyNils Florian Trautwein, Clemens Hinterleitner, Lena Sophie Kiefer, et al.
Science Advances|October 25, 2024
Functional PET/MRI reveals active inhibition of neuronal activity during optogenetic activation of the nigrostriatal pathwaySabrina Haas, Fernando Bravo, Tudor M Ionescu, et al.
Oncotarget|April 13, 2016
Preclinical evaluation of the anti-tumor effects of the natural isoflavone genistein in two xenograft mouse models monitored by [18F]FDG, [18F]FLT, and [64Cu]NODAGA-cetuximab small animal PETValerie S Honndorf, Stefan Wiehr, Anna-Maria Rolle, et al.
Theranostics|June 28, 2019
Imaging fibrosis in inflammatory diseases: targeting the exposed extracellular matrixNicolas Beziere, Kerstin Fuchs, Andreas Maurer, et al.
Neuroimage|November 24, 2007
[11C]PIB binding in Parkinson's disease dementiaWalter Maetzler, Matthias Reimold, Inga Liepelt, et al.
EJNMMI Physics|February 5, 2025
Low-activity [<sup>18</sup>F]-somatostatin receptor (SSTR) imaging using [<sup>18</sup>F]SiTATE on a long axial field-of-view PET/CT scannerNils F Trautwein, Eduardo Calderón, Pia M Linder, et al.
Pageof 11